## **Supplementary Material 1**

Cardiovascular outcomes and fracture risk after the discontinuation of preventative medications in older patients with complex health needs: a self-controlled case series analysis




Figure S1: Self-controlled case series design Within each patient's follow-up, event rates during exposed (treatment period) and unexposed (post-discontinuation) time windows are compared.




Figure S2: Study inclusion flowchart for the hospitalisation cohort




Figure S3: Study inclusion flowchart for the frailty cohort




Figure S4: Study inclusion flowchart for the polypharmacy cohort




Figure S5: Self-controlled case series in the hospitalisation cohort.

N(Persons) = Number of persons, N(Events) = Number of events, PY = patient years, IRR = Incidence rate ratio, CI = 95% confidence intervals




Figure S6: Self-controlled case series in the frailty cohort.

N(Persons) = Number of persons, N(Events) = Number of events, PY = patient years, IRR = Incidence rate ratio, CI = 95% confidence intervals




Figure S7: Self-controlled case series in the polypharmacy cohort.

N(Persons) = Number of persons, N(Events) = Number of events, PY = patient years, IRR = Incidence rate ratio, CI = 95% confidence intervals




Figure S8: Self-controlled case series in the complex health needs cohort (CHN).

N(Persons) = Number of persons, N(Events) = Number of events, PY = patient years, IRR = Incidence rate ratio, CI = 95% confidence intervals




Figure S9: Self-controlled case series in the hospitalisation cohort.

N(Persons) = Number of persons, N(Events) = Number of events, PY = patient years, IRR = Incidence rate ratio, CI = 95% confidence intervals




Figure S10: Self-controlled case series in the frailty cohort.

N(Persons) = Number of persons, N(Events) = Number of events, PY = patient years, IRR = Incidence rate ratio, CI = 95% confidence intervals




Figure S11: Self-controlled case series in the polypharmacy cohort.

N(Persons) = Number of persons, N(Events) = Number of events, PY = patient years, IRR = Incidence rate ratio, CI = 95% confidence intervals




Figure S12: Assumption testing for cardiovascular events in CHN cohort. Distribution of number of events relative to treatment end and start for antihypertensives and statins.




Figure S13: Assumption testing for fractures in CHN cohort. Distribution of number of events relative to treatment end and start of bisphosphonates.

Table S1: Follow-up duration in year for people with and without events in CHN cohort without previous use of respective preventative medication

	1 <sup>st</sup> Qu. [years]	Median [years]	3 <sup>rd</sup> Qu. [years]	
Antilom outon since we've we are le				
Antihypertensives-naïve people				
with MI	3.20	5.24	6.91	
without MI	1.81	4.21	5.93	
with stroke	2.77	4.78	6.65	
without stroke	1.80	4.21	5.93	
Bisphosphonate-naïve people with fractures	3.44	5.23	6.74	
Bisphosphonate-naïve people				
without fractures	1.76	3.99	5.83	
Statin-naïve people				
with MI	2.83	4.57	6.28	
without MI	1.68	3.81	5.78	
with stroke	2.66	4.54	6.28	
without stroke	1.68	3.81	5.77	

**Table S2: Number of events per person** in CHN cohort without previous use of respective preventative medication.

	Number of events per person						
	1	2	3	4	5	6	
Myocardial infarction							
In antihypertensives-naïve people	841	51	<5	<5			
In statin-naïve people	2,021	152	17				
Fractures							
In bisphosphonate-naïve people	15,478	2,565	448	88	22	5	
Stroke							
In antihypertensives-naïve people	1,123	104	9	<5			
In statin-naïve people	2,696	247	18	<5			